title: Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.
abstract: Mitotane is currently employed as adjuvant therapy as well as in the medical treatment of adrenocortical carcinoma (ACC), alone or in combination with chemotherapeutic agents. It was previously demonstrated that mitotane potentiates chemotherapeutic drugs cytotoxicity in cancer cells displaying chemoresistance due to P-glycoprotein (P-gp), an efflux pump involved in cancer multidrug resistance. The majority of ACC expresses high levels of P-gp and is highly chemoresistent. The aim of our study was to explore in vitro whether mitotane, at concentrations lower than those currently reached in vivo, may sensitize ACC cells to the cytotoxic effects of doxorubicin and whether this effect is due to a direct action on P-gp. NCI-H295 and SW13 cell lines as well as 4 adrenocortical neoplasia primary cultures were treated with mitotane and doxorubicin, and cell viability was measured by MTT assay. P-gp activity was measured by calcein and P-gp-Glo assays. P-gp expression was evaluated by Western blot. We found that very low mitotane concentrations sensitize ACC cells to the cytotoxic effects of doxorubicin, depending on P-gp expression. In addition, mitotane directly inhibits P-gp detoxifying function, allowing doxorubicin cytotoxic activity. These data provide the basis for the greater efficacy of combination therapy (mitotane plus chemotherapeutic drugs) on ACC patients. Shedding light on mitotane mechanisms of action could result in an improved design of drug therapy for patients with ACC.
authors.affiliation: Section of Endocrinology, Department of Medical Sciences, University of Ferrara, Via A. Moro, 8, 44124, Ferrara, Italy.
authors.forename: Teresa
authors.initials: T
authors.lastname: Gagliano
authors.forename: Erica
authors.initials: E
authors.lastname: Gentilin
authors.forename: Katiuscia
authors.initials: K
authors.lastname: Benfini
authors.forename: Carmelina
authors.initials: C
authors.lastname: Di Pasquale
authors.forename: Martina
authors.initials: M
authors.lastname: Tassinari
authors.forename: Simona
authors.initials: S
authors.lastname: Falletta
authors.forename: Carlo
authors.initials: C
authors.lastname: Feo
authors.forename: Federico
authors.initials: F
authors.lastname: Tagliati
authors.forename: Ettore Degli
authors.initials: ED
authors.lastname: Uberti
authors.forename: Maria Chiara
authors.initials: MC
authors.lastname: Zatelli
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000306:Adrenal Cortex Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018268:Adrenocortical Carcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology* / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology* / Q000627:therapeutic use; D016923:Cell Death / Q000187:drug effects*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004317:Doxorubicin / Q000494:pharmacology* / Q000627:therapeutic use; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D008939:Mitotane / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000903:Antibiotics, Antineoplastic; D018931:Antineoplastic Agents, Hormonal; D008939:Mitotane; D004317:Doxorubicin
references.citation: Am J Pathol. 2011 Feb;178(2):838-52
references.pmid: 21281816
references.citation: N Engl J Med. 2007 Jun 7;356(23):2372-80
references.pmid: 17554118
references.citation: Eur J Pharm Sci. 2010 Nov 20;41(3-4):458-63
references.pmid: 20688160
references.citation: Endocrinology. 2006 Jul;147(7):3530-8
references.pmid: 16601140
references.citation: Cancer. 2002 May 1;94(9):2333-43
references.pmid: 12015757
references.citation: Endocr Relat Cancer. 2013 Jun 24;20(4):463-75
references.pmid: 23653462
references.citation: J Endocrinol. 1998 Dec;159(3):373-80
references.pmid: 9834454
references.citation: Endocr Relat Cancer. 2008 Dec;15(4):1043-53
references.pmid: 18824557
references.citation: J Clin Endocrinol Metab. 1991 Jul;73(1):18-29
references.pmid: 1675220
references.citation: J Clin Endocrinol Metab. 2010 Feb;95(2):968-76
references.pmid: 19965918
references.citation: Eur J Cancer. 1993;29A(7):1036-8
references.pmid: 8098948
references.citation: J Endocrinol. 2013 Jul 29;218(3):275-85
references.pmid: 23814013
references.citation: Endocrine. 2014 Jun;46(2):181-98
references.pmid: 24272603
references.citation: J Clin Endocrinol Metab. 2013 Dec;98(12):4551-64
references.pmid: 24081734
references.citation: Endocrinology. 2010 Jun;151(6):2453-61
references.pmid: 20392828
references.citation: Surgery. 1991 Dec;110(6):1006-13
references.pmid: 1745969
references.citation: N Engl J Med. 2012 Jun 7;366(23):2189-97
references.pmid: 22551107
references.citation: Cell Oncol. 2009;31(6):457-65
references.pmid: 19940361
references.citation: Endocr Relat Cancer. 2014 Apr 28;21(3):383-94
references.pmid: 24532475
references.citation: Srp Arh Celok Lek. 2008 Mar-Apr;136(3-4):187-92
references.pmid: 18720757
references.citation: Am J Cardiol. 2013 Dec 15;112(12):1980-4
references.pmid: 24075281
references.citation: J Clin Endocrinol Metab. 2006 Jun;91(6):2218-24
references.pmid: 16569735
references.citation: Biochem Biophys Res Commun. 2002 Oct 4;297(4):828-34
references.pmid: 12359227
references.citation: Steroids. 1998 May-Jun;63(5-6):243-5
references.pmid: 9618778
references.citation: Reprod Toxicol. 2014 Jun;45:71-6
references.pmid: 24486453
references.citation: J Endocrinol Invest. 2014 Mar;37(3):207-17
references.pmid: 24458831
references.citation: J Clin Endocrinol Metab. 2005 Oct;90(10):5754-60
references.pmid: 16091477
references.citation: Endocr Relat Cancer. 2010 Jul 28;17(3):719-29
references.pmid: 20554786
references.citation: J Clin Endocrinol Metab. 2000 Feb;85(2):847-52
references.pmid: 10690900
references.citation: Endocr Relat Cancer. 2013 Jun 27;20(4):537-50
references.pmid: 23722227
references.citation: Eur J Cancer Prev. 2013 Jan;22(1):8-10
references.pmid: 22504657
references.citation: Int J Oncol. 1999 Jan;14(1):133-8
references.pmid: 9863019
references.citation: Pharmacogenomics. 2008 Jan;9(1):105-27
references.pmid: 18154452
references.citation: Endocr Relat Cancer. 2007 Dec;14(4):1029-38
references.pmid: 18045954
references.citation: J Clin Oncol. 2009 Sep 20;27(27):4619-29
references.pmid: 19667279
references.citation: Surgery. 1992 Dec;112(6):981-6
references.pmid: 1360713
references.citation: Am J Physiol Cell Physiol. 2000 Jun;278(6):C1256-65
references.pmid: 10837354
references.citation: J Biol Chem. 1987 Jan 15;262(2):505-8
references.pmid: 3027054
references.citation: Endocr Relat Cancer. 2013 May 30;20(3):443-54
references.pmid: 23507702